7/6/15
Today I read a study about dabigatran reversal with idarucizumab which is an antibody fragment to reverse the effects of dabigatran. Although this study is still in progress, it looked at the first 90 patients who were enrolled in the study. It grouped people into two groups: 1) had serious bleeding and 2) required an urgent procedure. Overall, in these patients the test results (dilute thrombin time and clotting test) were reversed in 88-98% of patients in minutes. In all the patients who received the reversal medication, only one patient had a thrombotic event before restarting anti-thrombotic therapy.
No comments:
Post a Comment